Home » Newsletters » BioWorld

BioWorld

March 19, 2008

View Archived Issues

Possible Vasculitis Case Halts Heplisav Trials, Dynavax Falls

The news sent shares of Dynavax (NASDAQ:DVAX) plunging 58.6 percent, closing Tuesday at $2.16, down $3.06. (BioWorld Today) Read More

Nuvelo Halting Alfimeprase After Phase II Study Failure

Approval Letter on Ceftobiprole Sends Basilea Shares Plunging

Alimera Closes $30M Financing, Boosts Stake in Medidur FA

BioNumerik's Tavocept Shows Trend Only in 'Small' Phase III

Prometic, Sartorius Pact Taps into Asian Markets

Other News To Note

Clinic Roundup